Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
about
Interventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapyInterventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for the treatment of oral and oropharyngeal cancers: surgical treatmentInterventions for preventing oral mucositis for patients with cancer receiving treatmentEffect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trialsPBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial.Chemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment.Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospectsRadiation-Induced Oral MucositisEfficacy and tolerability of amifostine in elderly cancer patientsAmifostine: chemotherapeutic and radiotherapeutic protective effects.Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues.Xerostomia and the geriatric patient.Diagnosing, managing, and preventing salivary gland disorders.Feasibility of tomotherapy-based image-guided radiotherapy for locally advanced oropharyngeal cancerClinical applications of radioprotectors.Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment.Functional outcomes following chemoradiotherapy for head and neck cancer.Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy.Mechanism of the protective effect of phenylephrine pretreatment against irradiation-induced damage in the submandibular gland.Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study.Evaluation of current and upcoming therapies in oral mucositis prevention.The effect of amifostine on submandibular gland histology after radiation.Systematic review of amifostine for the management of oral mucositis in cancer patients.p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection.Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.Survey of Policies and Guidelines on Antioxidant Use for Cancer Prevention, Treatment, and Survivorship in North American Cancer Centers: What Do Institutions Perceive as Evidence?
P2860
Q24235217-96385CFC-5146-4F64-8DC0-8B44EC6C635BQ24235245-7EF51A2D-321F-43FB-A046-8BABC0C84350Q24235482-1DF8693D-BB46-4765-B087-640DFD33C928Q24242951-BA7585BE-0508-4316-9878-7FDB33F84345Q24243046-DA7059D1-2177-46EF-B920-21036B8D36B5Q28538411-A8E4A8BE-02C8-4F17-8AD4-719C183D38C3Q32137542-BD85373B-D5B8-4C2C-9CD4-DB76481C9D33Q33217865-0D7F2396-31DE-41BC-980C-665361CDF3F1Q33336782-5E432C07-A563-4D95-9D95-A1EE28581CE8Q33399402-5094EB83-E9C4-4F22-A57E-B15518DAF2E3Q33653212-8173BCA1-1A5A-4853-9568-0A28D25EEFC1Q33711362-9069F4A0-40DF-40DB-8359-04C1B479E023Q33738758-F2FDD438-B626-4750-84D6-3482BC85D7F6Q34240906-B6937B8E-27DD-4FC6-8D9F-06AC258D810DQ34580440-85B184CA-D6A7-4BFA-8ED9-1EF40D55230CQ34593888-BDBFEF48-C862-4E0B-B425-CF848DE16BCFQ34625299-507FA33C-55FC-439D-9292-F41D51B89C82Q34653643-7EB10D5A-0751-4F20-9144-6320F9D4E094Q34734002-0AB93883-7123-4010-BC7E-9082A1B02CBAQ35079602-AE9A6FF6-FB12-4319-B571-ECC70F9C69BEQ35971325-88748C3C-98BD-4DEC-B572-122FA3EE7020Q36458432-3D7D52FB-03AB-4CCD-BA2C-AF181DD7E1D9Q36603888-A4931064-256B-4C9F-9231-9386A50DC063Q36891296-0E13EC78-41A8-42E7-B06D-D7B8ECDAF33BQ37818225-ED3E8870-D81E-4AB5-ACCE-8308D249CE39Q38030528-C6A9E15E-329B-4E26-9CAB-D90160A77B87Q38050986-BAF39059-65FC-4A82-9A0D-66BA10D14D58Q38293704-C6666C4E-36F0-46CC-9F96-FA2C32A18D1DQ38651513-FDD2A730-F60F-457C-86F2-D144067B1F2BQ43429878-452499AF-CAF0-4707-88EA-CC9A018C1BAE
P2860
Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Selective cytoprotection with ...... rapy for head and neck cancer.
@ast
Selective cytoprotection with ...... rapy for head and neck cancer.
@en
type
label
Selective cytoprotection with ...... rapy for head and neck cancer.
@ast
Selective cytoprotection with ...... rapy for head and neck cancer.
@en
prefLabel
Selective cytoprotection with ...... rapy for head and neck cancer.
@ast
Selective cytoprotection with ...... rapy for head and neck cancer.
@en
P2093
P356
P1433
P1476
Selective cytoprotection with ...... rapy for head and neck cancer.
@en
P2093
P304
P356
10.1023/A:1008282412670
P577
1998-05-01T00:00:00Z